Predicting time to ovarian carcinoma recurrence using protein markers

Abstract

Patients with ovarian cancer are at high risk of tumor recurrence. Prediction of therapy outcome may provide therapeutic avenues to improve patient outcomes. Using reverse-phase protein arrays, we generated ovarian carcinoma protein expression profiles on 412 cases from TCGA and constructed a PRotein-driven index of OVARian cancer (PROVAR). PROVAR significantly discriminated an independent cohort of 226 high-grade serous ovarian carcinomas into groups of high risk and low risk of tumor recurrence as well as short-term and long-term survivors. Comparison with gene expression-based outcome classification models showed a significantly improved capacity of the protein-based PROVAR to predict tumor progression. Identification of protein markers linked to disease recurrence may yield insights into tumor biology. When combined with features known to be associated with outcome, such as BRCA mutation, PROVAR may provide clinically useful predictions of time to tumor recurrence.

TCPA: a resource for cancer functional proteomics data

“…RPPA is a quantitative, antibody-based technology that can assess multiple protein markers in many samples in a cost-effective, sensitive and high-throughput manner 1,2 . This technology has been extensively validated for both cell line and patient samples 3–5 , and its applications range from building reproducible prognostic models 6 to generating experimentally verified mechanistic insights 7 .…”

“…The current data release covers 4,379 tumor samples and consists of three parts (Supplementary Table 2). These are (i) TCGA tumor tissue sample sets: 3,467 samples from 11 cancer types, to be extended to 25 cancer types; (ii) independent tumor tissue sample sets: one endometrial tumor set (244 samples) 7 and two ovarian tumor sets (99 and 130 samples, respectively) 6 , with other independent sets to be added soon; and (iii) tumor cell lines: 439 samples in four cell line sets, including both baseline and drug-treated cell lines. To our knowledge, this represents the largest publicly available collection of cancer functional proteomics data with parallel DNA and RNA data.…”

A Rare Case of Peritoneal Disseminated Angiosarcoma 20 Years after Ovarian Cancer Diagnosis

“…In up to 80% of patients, the disease recurs within 2-3 years, and most of them die within the next 5 years [12]. We are still looking for the prognostic factors that help predict the course of the disease and also improve the overall survival [12,13,14,15].…”

“…In up to 80% of patients, the disease recurs within 2-3 years, and most of them die within the next 5 years [12]. We are still looking for the prognostic factors that help predict the course of the disease and also improve the overall survival [12,13,14,15]. The case described involved peritoneal dissemination in a patient treated previously for ovarian cancer, suggesting peritoneal dissemination associated with the primary tumor, and as such it is the first in the literature.…”

Proteomics of ovarian cancer: functional insights and clinical applications

“…In a recent study, Yang et al . developed an algorithm (PROVAR) of nine proteins to determine tumor recurrence and progression based on RPPA protein profiles of TCGA samples that still need further validation [100]. Lee et al .…”